Jump to any asset
849 assets, updated daily
As of September 16, 2026, Neogen Corp. (NEOG) trades at $12.25. CleaRank Financial AI rates it Buy with a fair value of $12.25, in line with the current price. Wall Street's consensus target is $14.00 across 4 analysts. RSI at 69 is in neutral territory, and the price is above its 50-day average of $11.03.
Neogen Corp. (NEOG)
Neogen Corp. NASDAQ
$12.25
0.3000 (2.51%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
75 / 100
Neogen Corp. is trading at $12.25, reflecting a recent upgrade to 'Overweight' from Piper Sandler on August 26, 2026. The company's stock has shown bullish momentum, trading above its 50-day and 200-day moving averages ($11.03 and $9.55), with an RSI of 68.94. insiders are net sellers, with $779.3K in purchases versus no sales, indicating confidence in the company's prospects. Despite a slight revenue contraction of -0.1% year-over-year and negative EPS of -0.04, Neogen's profit margin remains negative at -0.91%. However, its price-to-sales ratio of 2.99 is below the sector median of 3.7, suggesting a potential valuation discount relative to peers. The company's debt-to-equity ratio of 0.39 is also within a reasonable range. The primary risks revolve around the negative profitability and the need to reignite revenue growth.
NEOG Price Analysis
Market Metrics
Open
$11.95
Day Range
$11.85 to $12.37
Prev Close
$11.95
Volume
3.28M
52-Week Range
$4.90 to $12.85
Market Cap
$2.67B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+2,612%), suggesting market expectations for superior growth or market position.
NEOG Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 2 quarters, NEOG beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
NEOG Analysis
Company's Health
4/5
12-Month Analyst Target
+14.29% Upside
Median of 4 analysts (12-month)
$14.00
AI Technical Analysis
Volume has increased 31.3% above its average, signaling heightened investor interest in Neogen Corp. The stock is trading above its 50-day SMA of $11.03 and its 200-day SMA of $9.55, indicating a positive short-to-medium term trend. The Relative Strength Index (RSI) is at 68.94, classifying it as bullish momentum, suggesting continued upward pressure. Key support levels are around the 50-day SMA, while resistance may be found near recent highs. The MACD indicator is positive at 0.24, further supporting the bullish sentiment. The stock's current price action suggests a continuation of the upward trend, supported by strong volume and positive technical indicators.
ProTips
- Insider buying activity, with $779.3K in purchases and no reported sales, signals strong conviction from management and warrants close observation.
- The stock is trading above key moving averages (50-day and 200-day SMA) with bullish RSI momentum, suggesting potential for further price appreciation.
- Focus on Neogen's ability to achieve sustainable profitability and reignite revenue growth, as these factors are critical for long-term value creation and may outweigh short-term EPS beats.
Key Catalysts
Bullish
Insider Net Buying Activity
Insiders have made net purchases totaling $779.3K with no reported sales, indicating strong confidence in the company's future prospects and potential for stock appreciation.
Source: Insider Trading DataBullish
Analyst Upgrade to Overweight
Piper Sandler upgraded Neogen Corp. to 'Overweight' on August 26, 2026, signaling positive sentiment from sell-side analysts and potentially attracting further investor interest.
Source: Analyst RatingsBullish
Positive Technical Momentum
The stock is trading above its 50-day and 200-day moving averages ($11.03 and $9.55) with a bullish RSI, suggesting a favorable technical setup for potential price increases.
Source: Technical AnalysisBearish
Negative Profitability and EPS
Neogen Corp. continues to report negative profit margins and EPS, which could limit investor appetite and valuation multiples if not addressed.
Source: Company FinancialsNeutral
Recent Earnings Beat with Negative Price Reaction
Despite beating EPS estimates, the stock has seen negative price reactions, indicating that market focus may be on broader profitability and revenue trends rather than short-term earnings surprises.
Source: Earnings ReportsMarket Outlook
Neogen Corp.'s base case scenario anticipates continued upward momentum, supported by strong insider selling and a median analyst price target of $14.00, suggesting a 14.3% upside from the current $12.25 price. The company's ability to leverage its market position in medical devices and diagnostics, coupled with a return to positive revenue growth and improved profitability, will be critical for achieving this target. Potential catalysts for upside include successful product launches or market share gains, which could accelerate revenue growth and improve margins. Conversely, a failure to translate sales into profitability, increased competition, or a broader market downturn could pressure the stock. The company's negative profit margin remains a key area to monitor for a sustained turnaround.
Key Statistics
| Market Cap | 2.67B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -0.0400 |
| Dividend Yield | 0.00% |
| 52 Week High | 12.85 |
| 52 Week Low | 4.90 |
Neogen Corp. presents a mixed fundamental picture with a price-to-sales ratio of 2.99, which is lower than the sector median of 3.7, indicating a potential valuation advantage. The company's profit margin is negative at -0.91%, and its return on equity is -0.38%, reflecting current profitability challenges. However, the company maintains a debt-to-equity ratio of 0.39, suggesting a manageable debt load. While revenue growth has been slightly negative at -0.1%, forward estimates suggest a return to positive growth, with next year's revenue projected to grow by 2.00%. The company's ability to translate its sales into profitability will be key to its long-term success.
Earnings & Growth Analysis
Neogen Corp. has demonstrated a pattern of beating earnings estimates in recent quarters. For the quarter ending March 2026, actual EPS was $0.13, surpassing the estimate of $0.11 by 18.18%, although the stock experienced a -4.42% price decline. Prior to that, the quarter ending March 2026 saw an even larger beat of 80% ($0.09 actual vs. $0.05 estimate), followed by a -6.18% stock price drop. Despite these positive earnings surprises, the stock price reactions have been negative, suggesting that market sentiment may be more focused on revenue growth and overall profitability rather than short-term EPS beats. Forward estimates indicate a return to positive revenue growth in the upcoming quarters.
Key Risks
Neogen Corp. faces risks related to its current negative profitability, with a net profit margin of -0.91% and a negative EPS of -0.04. While revenue growth is expected to turn positive, the company must demonstrate a clear path to sustained profitability to justify its current valuation. Additionally, the recent negative stock price reactions following positive earnings surprises suggest that investor sentiment may be cautious, requiring a stronger catalyst to drive sustained upside.
Technical Indicators
| RSI (14) | 68.94 |
|---|---|
| MACD | 0.24 |
| SMA 50 | 11.03 |
| SMA 200 | 9.55 |
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($11.03) above the 200-day SMA ($9.549), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.08
Weak correlation
Nasdaq 100 (QQQ)
+0.06
Weak correlation
Bitcoin (BTC)
+0.08
Weak correlation
Gold (XAU)
-0.04
Weak correlation
Check Custom Correlation
How does any other asset move with NEOG? One year of daily closes, Pearson correlation.
Try
NEOG Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$12.01
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$12.25
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$11.16
MAX LOSS
-7.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (68.9) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$12.61
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$13.21
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$13.81
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for NEOG is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in NEOG in September 2016 would be worth about $5,610 today, compared with about $35,497 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NEOG today could grow to about $9,822 by 2036 in the base case, with a bull case near $55,006 and a bear case around $1,754. Projections are statistical simulations, not guarantees.
NEOG Stock Price Prediction: 2030
CleaRank's simulation projects a price near $12.16 for NEOG by 2030 in the base case, from $12.25 today (1.0x over 4 years). The downside path ends near $4.09. These are outcomes of a Monte Carlo simulation run on NEOG's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $7.09 | $12.23 | $21.08 |
| 2028 | $5.65 | $12.21 | $26.37 |
| 2029 | $4.74 | $12.18 | $31.30 |
| 2030 | $4.09 | $12.16 | $36.16 |
| 2031 | $3.59 | $12.14 | $41.05 |
| 2032 | $3.19 | $12.12 | $46.03 |
| 2033 | $2.86 | $12.10 | $51.13 |
| 2034 | $2.59 | $12.07 | $56.38 |
| 2035 | $2.35 | $12.05 | $61.79 |
| 2036 | $2.15 | $12.03 | $67.38 |
Method: 10,000 simulated price paths using NEOG's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
NEOG Insider Trading Analysis
Bought
$779.3K
15 Transactions
Sold
None
No open-market sells
Insiders
20
Active Traders
Avg Transaction
$52.0K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 18, 2020 | HERBERT JAMES L
Director
|
Sell | 89.5K | $6.4M |
| Jul 18, 2019 | HERBERT JAMES L
Director
|
Sell | 56.2K | $3.7M |
| Mar 31, 2021 | ADENT JOHN EDWARD
Chief Executive Officer
|
Sell | 40.5K | $3.6M |
| Jan 31, 2019 | HERBERT JAMES L
Director
|
Sell | 49.4K | $2.9M |
| Mar 31, 2021 | MORRICAL TERRI A
Divisional Officer
|
Sell | 31.4K | $2.8M |
| Jan 16, 2020 | MORRICAL TERRI A
Officer
|
Sell | 39.5K | $2.8M |
| Nov 23, 2018 | HERBERT JAMES L
Officer and Director
|
Sell | 44.8K | $2.7M |
| Jan 22, 2019 | HERBERT JAMES L
Chairman of the Board
|
Sell | 45.3K | $2.7M |
| Jan 13, 2021 | PAPESH G BRUCE
Director
|
Sell | 30.0K | $2.5M |
| Apr 18, 2019 | HERBERT JAMES L
Director
|
Sell | 41.0K | $2.3M |
Page 1 of 1
Frequently Asked Questions
What is Neogen's stock price forecast for 2030?
Based on Monte Carlo simulations, Neogen's stock price is projected to be $12.16 in 2030 under a base case scenario. The downside projection is $4.09, while the upside projection reaches $36.16. These figures represent statistical outcomes and are not guaranteed price targets.
Is Neogen Corp. a buy right now?
Neogen Corp. is currently rated a 'Buy' with a consensus score of 75. The stock exhibits bullish technical momentum and strong insider selling, with a median analyst price target of $14.00, suggesting a 14.3% upside from the current price of $12.25.
What are the key risks for Neogen Corp. investors?
The primary risks for Neogen Corp. include its current negative profitability, evidenced by a negative net profit margin and EPS, and the need to reignite revenue growth. Recent stock price reactions to earnings beats also suggest cautious investor sentiment.
How does Neogen Corp. compare to its sector peers?
Neogen's price-to-sales ratio of 2.99 is below the sector median of 3.7, indicating a potential valuation discount. However, its profit margin and revenue growth are currently lagging behind the sector averages.
What is the latest analyst sentiment on Neogen Corp. stock?
The latest Wall Street consensus for Neogen Corp. is 'Strong Buy', with 2 out of 4 analysts rating it as such. The median analyst price target is $14.00, implying a 14.3% upside potential from the current stock price.
What are the recent earnings trends for Neogen Corp.?
Neogen Corp. has consistently beaten EPS estimates in recent quarters, including an 18.18% surprise in the quarter to March 2026. Despite these beats, the stock has seen negative price reactions, indicating a focus on broader profitability and revenue trends.
What is the outlook for Neogen Corp.'s revenue growth?
While Neogen Corp. experienced a slight revenue contraction of -0.1% recently, forward estimates project a return to positive growth. Next quarter's revenue is expected to grow by 2.00% year-over-year, and current year revenue growth is estimated at 1.00%.